Blockchain Registration Transaction Record

AI blood test pioneer Cardio Diagnostics targets heart disease

Cardio Diagnostics Holdings (NASDAQ: CDIO) advances AI-powered blood test for early detection of cardiovascular disease, leveraging multi-omic biomarkers to enable personalized treatment and reduce healthcare costs.

This news matters because cardiovascular disease is the leading cause of death globally, and current detection methods often miss early warning signs. Cardio Diagnostics' AI-driven blood test could enable earlier, more personalized interventions, potentially saving lives and reducing healthcare costs. For patients, this means a simple blood draw could replace invasive procedures and provide actionable insights into their heart health, empowering them to take preventive measures. For healthcare providers, it offers a powerful tool to identify high-risk individuals before symptoms appear, transforming cardiac care from reactive to proactive.